Importance of achieving lower blood pressure in hypertensive patients with diabetes

Hypertension

Volumn 44, Issue 5, 2004, Pages 614-615

  Brooks, Charles S ^a   Sowers, James R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CONTROL; EDITORIAL; HEART INFARCTION; HUMAN; HYPERTENSION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION;

EID: 7244236387     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000143853.53256.f8     Document Type: Editorial

References (10)

1. Bakris George L, Bakris Gaxiola, Efrain Messerli, Franz H, Mancia Giuseppe, Erdine Serap, Cooper-DeHoff Rhonda, Pepine Carl J. Clinical outcomes in the diabetes cohort of the INVEST. Hypertension. 2004;44:637-642.
2. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA. 2003;289:2073-2082.
3. Lindholm LH, Ibsen H, Dahlog B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359:1004-1010.
4. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with diuretic/beta-blocker- based treatment regiment: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
6. McFarlane S, Jacober S, Winer N, Kaur J, Castro J, Wui M, Gliwa A, Gizycki H, Sowers J. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718-723.
7. Singer GM, Izhar M, Black HR. Guidelines for hypertension: are quality-assurance measures on target? Hypertension. 2004;43:198-202.
8. ALLHAT Officers and Coordinators, ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-convertin enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
9. Hansson L, Zanchetti I, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
10. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-2031.